Connection

JAMES WELSH to Animals

This is a "connection" page, showing publications JAMES WELSH has written about Animals.
Connection Strength

0.986
  1. Superior antitumor immune response achieved with proton over photon immunoradiotherapy is amplified by the nanoradioenhancer NBTXR3. J Nanobiotechnology. 2024 Oct 01; 22(1):597.
    View in: PubMed
    Score: 0.042
  2. Inhibition of MER proto-oncogene tyrosine kinase by an antisense oligonucleotide enhances treatment efficacy of immunoradiotherapy. J Exp Clin Cancer Res. 2024 Mar 06; 43(1):70.
    View in: PubMed
    Score: 0.040
  3. Nanoparticle-enhanced proton beam immunoradiotherapy drives immune activation and durable tumor rejection. JCI Insight. 2023 06 22; 8(12).
    View in: PubMed
    Score: 0.038
  4. NLRP3 agonist enhances radiation-induced immune priming and promotes abscopal responses in anti-PD1 resistant model. Cancer Immunol Immunother. 2023 Sep; 72(9):3003-3012.
    View in: PubMed
    Score: 0.038
  5. Inhibition of STAT6 with Antisense Oligonucleotides Enhances the Systemic Antitumor Effects of Radiotherapy and Anti-PD-1 in Metastatic Non-Small Cell Lung Cancer. Cancer Immunol Res. 2023 04 03; 11(4):486-500.
    View in: PubMed
    Score: 0.038
  6. NBTXR3 improves the efficacy of immunoradiotherapy combining nonfucosylated anti-CTLA4 in an anti-PD1 resistant lung cancer model. Front Immunol. 2022; 13:1022011.
    View in: PubMed
    Score: 0.037
  7. Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. Front Immunol. 2022; 13:984318.
    View in: PubMed
    Score: 0.036
  8. Combining a nanoparticle-mediated immunoradiotherapy with dual blockade of LAG3 and TIGIT improves the treatment efficacy in anti-PD1 resistant lung cancer. J Nanobiotechnology. 2022 Sep 19; 20(1):417.
    View in: PubMed
    Score: 0.036
  9. Ramsar, Iran, as a Natural Radiobiological Surrogate for Mars. Health Phys. 2022 04 01; 122(4):508-512.
    View in: PubMed
    Score: 0.035
  10. Novel Use of Low-Dose Radiotherapy to Modulate the Tumor Microenvironment of Liver Metastases. Front Immunol. 2021; 12:812210.
    View in: PubMed
    Score: 0.034
  11. Role of Mitochondria in Cancer Immune Evasion and Potential Therapeutic Approaches. Front Immunol. 2020; 11:573326.
    View in: PubMed
    Score: 0.032
  12. Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.032
  13. Bone morphogenetic protein 7 promotes resistance to immunotherapy. Nat Commun. 2020 09 24; 11(1):4840.
    View in: PubMed
    Score: 0.032
  14. Use of Multi-Site Radiation Therapy for Systemic Disease Control. Int J Radiat Oncol Biol Phys. 2021 02 01; 109(2):352-364.
    View in: PubMed
    Score: 0.031
  15. Combination treatment with radiotherapy and a novel oxidative phosphorylation inhibitor overcomes PD-1 resistance and enhances antitumor immunity. J Immunother Cancer. 2020 06; 8(1).
    View in: PubMed
    Score: 0.031
  16. SHP-2 and PD-L1 Inhibition Combined with Radiotherapy Enhances Systemic Antitumor Effects in an Anti-PD-1-Resistant Model of Non-Small Cell Lung Cancer. Cancer Immunol Res. 2020 07; 8(7):883-894.
    View in: PubMed
    Score: 0.031
  17. Triple Therapy with MerTK and PD1 Inhibition Plus Radiotherapy Promotes Abscopal Antitumor Immune Responses. Clin Cancer Res. 2019 12 15; 25(24):7576-7584.
    View in: PubMed
    Score: 0.030
  18. IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Int J Radiat Oncol Biol Phys. 2019 07 15; 104(4):903-912.
    View in: PubMed
    Score: 0.029
  19. Anti-glucocorticoid-induced Tumor Necrosis Factor-Related Protein (GITR) Therapy Overcomes Radiation-Induced Treg Immunosuppression and Drives Abscopal Effects. Front Immunol. 2018; 9:2170.
    View in: PubMed
    Score: 0.028
  20. Glycosylation and Antitumor Immunity. Int Rev Cell Mol Biol. 2019; 343:111-127.
    View in: PubMed
    Score: 0.027
  21. Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model. Clin Cancer Res. 2018 11 15; 24(22):5735-5743.
    View in: PubMed
    Score: 0.027
  22. Indoleamine 2,3-dioxygenase 1 inhibition targets anti-PD1-resistant lung tumors by blocking myeloid-derived suppressor cells. Cancer Lett. 2018 09 01; 431:54-63.
    View in: PubMed
    Score: 0.027
  23. Optimizing Radiotherapy with Immunotherapeutic Approaches. Adv Exp Med Biol. 2017; 995:53-71.
    View in: PubMed
    Score: 0.024
  24. Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy. Cancer Res. 2017 02 15; 77(4):839-850.
    View in: PubMed
    Score: 0.024
  25. PDL1 Regulation by p53 via miR-34. J Natl Cancer Inst. 2016 Jan; 108(1).
    View in: PubMed
    Score: 0.023
  26. Galectin-1 and immune suppression during radiotherapy. Clin Cancer Res. 2014 Dec 15; 20(24):6230-2.
    View in: PubMed
    Score: 0.021
  27. Combining radiation and immunotherapy: a new systemic therapy for solid tumors? Cancer Immunol Res. 2014 Sep; 2(9):831-8.
    View in: PubMed
    Score: 0.021
  28. Therapeutic delivery of miR-200c enhances radiosensitivity in lung cancer. Mol Ther. 2014 Aug; 22(8):1494-1503.
    View in: PubMed
    Score: 0.020
  29. Modulation of c-Met signaling and cellular sensitivity to radiation: potential implications for therapy. Cancer. 2013 May 15; 119(10):1768-75.
    View in: PubMed
    Score: 0.019
  30. The c-Met receptor tyrosine kinase inhibitor MP470 radiosensitizes glioblastoma cells. Radiat Oncol. 2009 Dec 22; 4:69.
    View in: PubMed
    Score: 0.015
  31. Novel engineered IL-2 Nemvaleukin alfa combined with PD1 checkpoint blockade enhances the systemic anti-tumor responses of radiation therapy. J Exp Clin Cancer Res. 2024 Sep 02; 43(1):251.
    View in: PubMed
    Score: 0.010
  32. A radioenhancing nanoparticle mediated immunoradiation improves survival and generates long-term antitumor immune memory in an anti-PD1-resistant murine lung cancer model. J Nanobiotechnology. 2021 Dec 11; 19(1):416.
    View in: PubMed
    Score: 0.009
  33. A comparison of proton stopping power measured with proton CT and x-ray CT in fresh postmortem porcine structures. Med Phys. 2021 Dec; 48(12):7998-8009.
    View in: PubMed
    Score: 0.009
  34. Radiation Therapy Enhanced by NBTXR3 Nanoparticles Overcomes Anti-PD1 Resistance and Evokes Abscopal Effects. Int J Radiat Oncol Biol Phys. 2021 11 01; 111(3):647-657.
    View in: PubMed
    Score: 0.008
  35. Safety and clinical activity of intratumoral MEDI9197 alone and in combination with durvalumab and/or palliative radiation therapy in patients with advanced solid tumors. J Immunother Cancer. 2020 10; 8(2).
    View in: PubMed
    Score: 0.008
  36. Role of miRNAs in immune responses and immunotherapy in cancer. Genes Chromosomes Cancer. 2019 04; 58(4):244-253.
    View in: PubMed
    Score: 0.007
  37. Role of Radiation Therapy in Modulation of the Tumor Stroma and Microenvironment. Front Immunol. 2019; 10:193.
    View in: PubMed
    Score: 0.007
  38. Cancer-associated rs6983267 SNP and its accompanying long noncoding RNA CCAT2 induce myeloid malignancies via unique SNP-specific RNA mutations. Genome Res. 2018 04; 28(4):432-447.
    View in: PubMed
    Score: 0.007
  39. Radiation therapy and immunotherapy: what is the optimal timing or sequencing? Immunotherapy. 2018 02 01; 10(4):299-316.
    View in: PubMed
    Score: 0.007
  40. Metastasis is regulated via microRNA-200/ZEB1 axis control of tumour cell PD-L1 expression and intratumoral immunosuppression. Nat Commun. 2014 Oct 28; 5:5241.
    View in: PubMed
    Score: 0.005
  41. CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer. Genome Res. 2013 Sep; 23(9):1446-61.
    View in: PubMed
    Score: 0.005
  42. Loss of biological effect in prolonged fraction delivery. Int J Radiat Oncol Biol Phys. 2004 May 01; 59(1):242-9.
    View in: PubMed
    Score: 0.003
  43. WISP-1 is a Wnt-1- and beta-catenin-responsive oncogene. Genes Dev. 2000 Mar 01; 14(5):585-95.
    View in: PubMed
    Score: 0.002
  44. WISP genes are members of the connective tissue growth factor family that are up-regulated in wnt-1-transformed cells and aberrantly expressed in human colon tumors. Proc Natl Acad Sci U S A. 1998 Dec 08; 95(25):14717-22.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.